Finding new drugs to target a specific protein in a deadly childhood cancer
Screening for Cys-Reactive Ligands to Target PAX3-FOXO1
This study is looking for new ways to find medicines that can help treat a serious childhood cancer called alveolar rhabdomyosarcoma by targeting a specific protein, and it's being done by a team of scientists working together to improve treatment options for kids with this condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10611002 on NIH RePORTER |
What this research studies
This research focuses on developing new drug identification strategies to target the PAX3-FOXO1 protein, which is involved in a severe form of pediatric cancer called alveolar rhabdomyosarcoma. The team will produce various forms of this protein and screen them against a library of potential drug candidates to find effective treatments. By using advanced techniques like covalent ligand screening and biochemical validation, the researchers aim to discover new therapeutic options that could improve outcomes for affected children. This collaborative effort combines expertise from multiple scientists to enhance the drug discovery process.
Who could benefit from this research
Good fit: Ideal candidates for this research are children diagnosed with alveolar rhabdomyosarcoma or those at risk for this condition.
Not a fit: Patients with other types of cancer or those not diagnosed with alveolar rhabdomyosarcoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, effective treatments for children suffering from a lethal form of cancer.
How similar studies have performed: While targeting transcription factors has been challenging, there is ongoing research exploring similar approaches, indicating potential for success in this area.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Linardic, Corinne Mary — Duke University
- Study coordinator: Linardic, Corinne Mary
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.